AbbVie increased its quarterly dividend to $1.73, raising its annual payout by 5.5% despite a 29% stock price rise this year, which lowers the yield to about 2.4%. The company’s dividend payout ratio is around 49.5% of adjusted earnings, supported by strong cash flow and growing sales of drugs like Skyrizi and Rinvoq, which offset declines in Humira. However, investors should monitor the impact of the $10.9 billion Apogee acquisition, which adds debt and slightly reduces earnings per share. AbbVie remains attractive for dividend growth investors but offers a lower current yield after the recent rally.
AbbVie's dividend increase story fits with its strong performance on Pluang, where the stock reached its 52-week high of USD 285.42 as of Oct 17, 2026 19:11 WIB. The dividend yield stands at 2.42%, closely matching the article's figure, while investor sentiment leans bullish with 73% of order activity on the buy side. The stock also gained 1.34% in the last day, reflecting ongoing investor interest.
AbbVie unveiled 20 new scientific presentations at the 2026 United European Gastroenterology Week, highlighting long-term and real-world data for its inflammatory bowel disease (IBD) treatments SKYRIZI (risankizumab) and RINVOQ (upadacitinib). The da...
Eli Lilly trades at a premium 24x forward earnings but shows revenue growth of 47.7% year-over-year, far surpassing major pharma peers like Novo Nordisk and AbbVie. The company raised its 2026 revenue guidance twice, aiming for $85B-$87B, driven by s...
